These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25784448)

  • 1. [Study on the treatment of nonmuscle invasive bladder cancer: A phase III efficacy study for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) AB 40/11 of the AUO].
    Rexer H;
    Urologe A; 2015 Mar; 54(3):406-8. PubMed ID: 25784448
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study for the treatment of nonmuscle invasive bladder cancer : A phase III efficacy trial for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) - AB 40/11 of the AUO].
    Rexer H;
    Urologe A; 2016 Jul; 55(7):963-5. PubMed ID: 27272001
    [No Abstract]   [Full Text] [Related]  

  • 3. Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study.
    Rose A; El-Leithy T; vom Dorp F; Zakaria A; Eisenhardt A; Tschirdewahn S; Rübben H
    J Urol; 2015 Oct; 194(4):939-43. PubMed ID: 25910967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
    Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U
    Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.
    Elsässer-Beile U; Leiber C; Wolf P; Lucht M; Mengs U; Wetterauer U
    J Urol; 2005 Jul; 174(1):76-9. PubMed ID: 15947582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the therapy of nonmuscle-invasive bladder cancer: treatment of nonmuscle-invasive high-grade urothelial cancer of the bladder with the standard number and dosage of intravesical BCG instillations versus a reduced number of intravesical BCG instillations in the standard dosage: a randomized phase 3 study of the European Association of Urology Research Foundation (NIMBUS - AB 37/10 of the AUO)].
    Rexer H
    Urologe A; 2014 Jun; 53(6):890-2. PubMed ID: 24821409
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice.
    Mengs U; Schwarz T; Bulitta M; Weber K
    Anticancer Res; 2000; 20(5B):3565-8. PubMed ID: 11131663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines.
    Urech K; Buessing A; Thalmann G; Schaefermeyer H; Heusser P
    Anticancer Res; 2006; 26(4B):3049-55. PubMed ID: 16886633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
    Hendricksen K; Witjes JA
    Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
    Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
    J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer.
    Cookson MS; Chang SS; Oefelein MG; Gallagher JR; Schwartz B; Heap K
    J Urol; 2012 May; 187(5):1571-6. PubMed ID: 22425105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
    Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
    J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.
    McKiernan JM; Barlow LJ; Laudano MA; Mann MJ; Petrylak DP; Benson MC
    J Urol; 2011 Aug; 186(2):448-51. PubMed ID: 21680003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer.
    Barocas DA; Liu A; Burks FN; Suh RS; Schuster TG; Bradford T; Moylan DA; Knapp PM; Murtagh DS; Morris D; Dunn RL; Montie JE; Miller DC
    J Urol; 2013 Dec; 190(6):2011-6. PubMed ID: 23792129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?
    Arends TJH; Alfred Witjes J
    Urol Clin North Am; 2020 Feb; 47(1):73-82. PubMed ID: 31757302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.